Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2

Interventions

enzalutamide 92Magnetic Resonance Spectroscopy 87Specimen Handling 66Prednisone 65Androgen Antagonists 59Abiraterone Acetate 59apalutamide 56Radiosurgery 53Radiotherapy 47Leuprolide 47darolutamide 46abiraterone 44Docetaxel 43Radiation 31Pluvicto 31acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 30Biopsy 30relugolix 28Surveys and Questionnaires 28pembrolizumab 26gallium 68 PSMA-11 26Standard of Care 26Triptorelin Pamoate 25Goserelin 25bicalutamide 23Gonadotropin-Releasing Hormone 23Brachytherapy 21Carboplatin 20X-Rays 19luprolide acetate gel depot 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms × orteronel × 1 year × Clear all
NCT01546987 2026-03-06

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Radiation Therapy Oncology Group

Phase 3 Completed
239 enrolled 38 charts
Genitourinary

Prostatic Neoplasms

NCT01809691 2025-12-31

S1216

SWOG Cancer Research Network

Phase 3 Completed
1,313 enrolled 22 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡